Results from a phase III randomized trial (ALSYMPCA) of radium-223 chloride, a first-in-class alpha-emitter, in patients with castration-resistant prostate cancer (CRPC) and bone metastases: overall survival benefit and safety profile

被引：0
|
作者：
O'Sullivan, J. M. [1 ]
Parker, C. [2 ]
Cross, A.
O'Bryan-Tear, C. G. [3 ]
Garcia-Vargas, J. [4 ]
Sartor, O. [5 ]
机构：
[1] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Algeta ASA, Oslo, Norway
[4] Bayer HealthCare Pharmaceut, Montville, NJ USA
[5] Tulane Canc Ctr, New Orleans, LA USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP689
引用
收藏
页码：S294 / S294
页数：1
相关论文
共 50 条
  • [31] PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES
    Tomblyn, Michael
    Nilsson, Sten
    Vogelzang, Nicholas
    Sartor, A. Oliver
    Cislo, Paul
    Van Gool, Renilt
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF UROLOGY, 2013, 189 (04): : E293 - E293
  • [32] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wiechno, P.
    Helle, S. I.
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S690 - S691
  • [33] Radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases receiving radium-233 chloride in a double-blind, randomized, phase III trial (ALSYMPCA)
    Lewington, V.
    Lamey, R.
    Staudacher, K.
    Vogelzang, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S304 - S304
  • [34] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S. I.
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    Tear, C. G. O'Bryan
    Shan, M.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [35] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wedel, S.
    Wiechno, P.
    Helle, S., I
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 86 - 87
  • [36] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
    Finkelstein, S. E.
    Michalski, J. M.
    O'Sullivan, J.
    Parker, C.
    Garcia-Vargas, J.
    Sartor, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
  • [37] RADIUM-223 CHLORIDE, A NOVEL, HIGHLY TARGETED ALPHA-PHARMACEUTICAL FOR TREATMENT OF BONE METASTASES FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): HEMATOLOGIC AND SAFETY PROFILE WITH REPEATED DOSING
    Parker, C.
    Aksnes, A.
    Haugen, I.
    Bolstad, B.
    Nilsson, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 277 - 278
  • [38] Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
    Hiroji Uemura
    Hirotsugu Uemura
    Nobuaki Matsubara
    Seigo Kinuya
    Makoto Hosono
    Yoko Yajima
    Toshihiko Doi
    International Journal of Clinical Oncology, 2017, 22 : 954 - 963
  • [39] Efficacy and Safety of Radium-223 Dichloride in the Treatment of Patients with Castration-Resistant Prostate Cancer with Bone Metastases
    Sanchez Lopez, Hector
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 1 - 2
  • [40] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, G.
    Fang, F.
    Vogelzang, N. J.
    ONKOLOGIE, 2013, 36 : 78 - 78
12345